A Phase 2, Double-Blind, Placebo-Controlled, 3-Month Trial of LY3298176 Versus Placebo in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2018
At a glance
- Drugs Tirzepatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 31 Aug 2018 Biomarkers information updated
- 27 Jul 2018 Status changed from active, no longer recruiting to completed.
- 10 Apr 2018 Planned End Date changed from 19 Apr 2018 to 30 Apr 2018.